This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on ISI (5)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Dermatology  • Immunization  • Papillomavirus, Human  • Women's Health, Other  • Alert me on articles by topic

Bridget M. Kuehn

JAMA. 2006;296:640-641.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

A vaccine that has been shown to prevent cervical cancer, precancerous genital lesions, and genital warts may soon become part of the schedule of vaccinations for preteen girls if leaders of the Centers for Disease Control and Prevention (CDC) and the Department of Health and Human Services follow the recommendation of a CDC scientific advisory panel.

In June, the CDC's Advisory Committee on Immunization Practices voted unanimously to recommend that girls aged 11 to 12 years be routinely vaccinated against the human papilloma virus (HPV), which can cause cervical cancer, precancerous genital lesions, and genital warts. Additionally, the committee recommended that girls as young as 9 years receive the vaccine at their physician's discretion and that females aged 13 to 26 years also be vaccinated. The recommendations apply to Gardasil, a vaccine developed by Merck (Whitehouse Station, NJ) and approved by the US Food and Drug Administration . . . [Full Text of this Article]

ENSURING ACCESS

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Human Papillomavirus Vaccine Legislation in Kentucky: A Policy Analysis
Dekker
Policy Politics Nursing Practice 2008;9:40-49.
ABSTRACT  

Screening, Diagnosis, and Treatment of Cancer in Long-Term Dialysis Patients
Holley
CJASN 2007;2:604-610.
ABSTRACT | FULL TEXT